INCY
USDIncyte Corp. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$101.360
Máximo
$103.860
Mínimo
$100.020
Volume
2.74M
Fundamentos da empresa
Capitalização de mercado
20.2B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
2.00M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated
Incyte to Present at Upcoming Investor Conferences
Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84
RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.
Ações relacionadas
INMD
InMode Ltd. Ordinary Shares
ACAD
ACADIA Pharmaceuticals Inc.
NSC
Norfolk Southern Railway
AIO
Virtus Artificial Intelligence & Technology Opportunities Fund Common Shares of Beneficial Interest
KPTI
Karyopharm Therapeutics Inc.
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.